CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has completed enrolling patients in all four previously announced prospective, open-label clinical studies investigating Soliris® (eculizumab) as a potential treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) being conducted in North America and multiple European countries. The four studies have achieved the Company’s enrollment targets, with a total of approximately 35 adult and adolescent patients with aHUS.
